Aberrant Activation of Androgen Pathways in African American Prostate Cancer
Official title: Aberrant Activation of Androgen Signaling Pathways in African American Prostate Cancer
Funded at New York University School of Medicine · NIH-11473158 · Data updated 2026-11-12
This study explores how genetic and epigenetic factors linked to androgen signaling may drive prostate cancer in African American men.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | June 1, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $413,396 |
| NIH project number | 7R01CA288392-03 |
| Project ID | NIH-11473158 on NIH RePORTER |
Who could benefit from this research
✓Could help
African American men diagnosed with or at risk for prostate cancer may be eligible for future translational studies stemming from this work.
✕Less likely to help
This study is primarily investigational and may not directly benefit all participants in the short term.
What this research studies
African American men face higher prostate cancer risk and mortality, and this project looks at how androgen receptor pathways and related genetic features contribute to that disparity. Researchers will examine AR signaling, its polyglutamine (PolyQ) tract length, and interactions with the Wnt pathway, to understand tumor behavior in AA prostate cancer. The work combines molecular analyses of human samples with approaches to link these signals to cancer growth and onset. Findings could point to targeted strategies tailored for AA patients facing prostate cancer.
Why it matters
Potential benefit: If successful, the work could lead to more precise risk assessment and future therapies tailored to African American men with prostate cancer.
How similar studies have gone: prior studies have shown associations between AR signaling, PolyQ length, and prostate cancer features, supporting the relevance of this approach.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Sun, Zijie — New York University School of Medicine
- Study coordinator: Sun, Zijie
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.